Diabetes Market
Diabetes Market By Type, By Drug Class, By Devices - Global Industry Share, Growth, Competitive Analysis And Forecast, 2018-2023 Update Available - Forecast 2024-2030
The global diabetes market is expected to grow at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is segmented on the basis of the type of diabetes, drugs class, and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 8.9%. Some of the top-selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lily And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lily And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show a strong growth rate. Diabetic drugs are highly priced which could be one of the major drawbacks.
Diabetic devices include blood glucose meters and insulin delivery devices. The market for blood glucose meters will have the highest market share compared to the insulin delivery systems such as syringes and injection pens. Continuous glucose monitoring systems will have the highest market growth. Meter and strips are expected to dominate the overall market share in diabetic devices.
Overall the market is driven by the growing burden of diabetes on economies. U.S. alone spends 11% of its health expenditure on diabetes. India and China are most affected by diabetes with over 120 million patients. A majority of diabetes patients are either undiagnosed or lack basic treatment. The impending unmet needs are forcing the companies and governments to provide basic needs for diabetes. Research and development is ongoing to develop long term solution for diabetes. Some of the leading manufacturers are trying to develop an artificial pancreas. Currently, CGMS devices are being used with insulin pumps as the secondary prototype for the artificial pancreas. It is expected that artificial pancreas will be ready for commercialization by the next decade. Development of artificial pancreas has gained support from USFDA, which is a major boost for the market.
North America is the leading geography followed by Europe and Asia Pacific. The Asia Pacific is expected to have the highest growth rate amongst the regions. North American market is driven by high awareness, availability of reimbursements and high expenditure on healthcare. Asia Pacific market is driven by the high population of diabetic patients.
The report provides detailed & insightful chapters which include market overview, key findings, strategic recommendations, market estimations, patent analysis, pipeline analysis, market determinants, key company analysis, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.
Market segments included in the report
- Diabetes by Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Drug Class
- Alpha-Glucosidase Inhibitors
- Amylin Analogs
- Antidiabetic Combinations
- Dipeptidyl Peptidase 4 Inhibitors
- Incretin Mimetics
- Insulin
- Meglitinides
- Non-Sulfonylureas
- Sglt-2 Inhibitors
- Sulfonylureas
- Thiazolidinediones
- Diabetic Devices
- Blood Glucose Meters
- Blood Glucose Strips
- Insulin Injection Pens
- Insulin Syringes
- Continuous Glucose Monitoring Systems
- Insulin Pumps
- Lancets
The report covers
- Comprehensive research methodology of the diabetes market
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global diabetes market
- Insights about market determinants which are stimulating the global diabetes market
- Detailed and extensive market segments with regional distribution of forecasted revenues
- Extensive profiles and recent developments of market players
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. PIPELINE ANALYSIS
2.3. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. REGULATIONS
2.4.1. TAX LAWS
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. INDIA
2.4.1.5. REST OF THE WORLD
2.4.2. DRUG AND DEVICE REGULATIONS
2.4.2.1. UNITED STATES
2.4.2.2. EUROPEAN UNION
2.4.2.3. CHINA
2.4.2.4. INDIA
2.4.2.5. JAPAN
2.4.3. TOP SELLING DIABETES DRUGS
2.4.3.1. LANTUS (SANOFI)
2.4.3.2. JANUVIA (MERCK AND CO)
2.4.3.3. HUMALOG (ELI LILY AND CO)
2.4.3.4. NOVORAPID/NOVOLOG (NOVO NORDISK)
2.4.3.5. LEVEMIR (NOVO NORDISK)
2.4.3.6. VICTOZA (NOVO NORDISK)
2.4.3.7. JANUMET (MERCK AND CO.)
2.4.3.8. HUMULIN (ELI LILY AND CO.)
2.4.3.9. TOUJEO (SANOFI)
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING PREVALENCE AND INCIDENCE RATE OF DIABETES
3.1.2. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
3.1.3. GROWING POPULARITY OF WEARABLE DEVICES AND POC SOLUTIONS
3.2. RESTRAINTS
3.2.1. NUMBER OF UNDIAGNOSED PATIENTS IN DEVELOPING COUNTRIES IS HIGH
3.2.2. CGMS AND INSULIN PUMPS DEVICES SALE LIMITED TO DEVELOPED MARKET
3.2.3. HIGH PRICE AND RECURRING COST
3.3. OPPORTUNITIES
3.3.1. EMERGING MARKETS
3.3.2. DEVELOPMENT OF ARTIFICIAL PANCREASES
3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON-INVASIVE MONITORING DEVICES
4. MARKET SEGMENTATION
4.1. DIABETES MARKET BY TYPE
4.1.1. TYPE 1 DIABETES
4.1.2. TYPE 2 DIABETES
4.1.3. GESTATIONAL
4.2. DIABETES MARKET BY DRUG CLASS
4.2.1. ALPHA-GLUCOSIDASE INHIBITORS
4.2.2. AMYLIN ANALOGS
4.2.3. ANTIDIABETIC COMBINATIONS
4.2.4. DIPEPTIDYL PEPTIDASE 4 INHIBITORS
4.2.5. INCRETIN MIMETICS
4.2.6. INSULIN
4.2.7. MEGLITINIDES
4.2.8. NON-SULFONYLUREAS
4.2.9. SGLT-2 INHIBITORS
4.2.10. SULFONYLUREAS
4.2.11. THIAZOLIDINEDIONE
4.3. DIABETES MARKET BY DEVICES
4.3.1. BLOOD GLUCOSE METERS
4.3.2. BLOOD GLUCOSE STRIPS
4.3.3. INSULIN INJECTION PENS
4.3.4. INSULIN SYRINGES
4.3.5. CONTINUOUS GLUCOSE MONITORING SYSTEMS
4.3.6. INSULIN PUMPS
4.3.7. LANCETS
5. COMPETITIVE LANDSCAPE
5.1. MARKET SHARE ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES INC
7.2. ALERE INC.
7.3. ASCENSIA DIABETES CARE
7.4. ASTRAZENECA LTD
7.5. BAYER AG
7.6. BECTON, DICKINSON AND COMPANY
7.7. BIOCON LTD.
7.8. BOEHRINGER INGELHEIM
7.9. BRISTOL-MYERS SQUIBB
7.10. CELLNOVO GROUP
7.11. DEXCOM INC
7.12. DIAMYD MEDICAL
7.13. ELI LILY AND CO.
7.14. F. HOFFMANN-LA ROCHE LTD.
7.15. GLAXOSMITHKLINE
7.16. GLENMARK
7.17. JOHNSON AND JOHNSON
7.18. JOSLIN DIABETES CENTER
7.19. LIFESCAN
7.20. LUPIN PHARMACEUTICALS LTD
7.21. MANNKIND CORPORATION
7.22. MEDTRONIC PLC
7.23. MERCK & CO.
7.24. MICRO LABS LTD
7.25. MSD PHARMACEUTICALS
7.26. NOVARTIS
7.27. NOVO-NORDISK
7.28. PFIZER
7.29. PROMETHEON PHARMA, LLC
7.30. SANOFI
7.31. SMITHS MEDICAL
7.32. SUN PHARMACEUTICALS INDUSTRIES LTD
7.33. TAKEDA PHARMACEUTICAL LTD.
7.34. TANDEM DIABETES CARE
7.35. THERMALIN, INC
7.36. USV PRIVATE LIMITED
TABLE # 1 GLOBAL DIABETES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023, ($ MILLION)
TABLE # 2 GLOBAL DIABETES MARKET RESEARCH AND ANALYSIS BY TYPE 2017-2023, ($ MILLION)
TABLE # 3 GLOBAL TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
TABLE # 4 GLOBAL TYPE2 DIABETES MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 5 GLOBAL GESTATIONAL MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 6 GLOBAL DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023, ($MILLION)
TABLE # 7 GLOBAL ALPHA GLUCOSIDASE INHIBITOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 8 GLOBAL AMYLIN ANALOGS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
TABLE # 9 GLOBAL ANTIDIABETIC COMBINATIONS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
TABLE # 10 GLOBAL DIPEPTIDYL PEPTIDASE 4 INHIBITOR MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 11 GLOBAL INCRETIN MIMETICS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 12 GLOBAL INSULIN MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 13 GLOBAL MEGLITINIDES MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 14 GLOBAL NON-SULFONYLUREAS MARKET RESEARCH AND ANALYSIS 2017-2023, ($ MILLION)
TABLE # 15 GLOBAL SGLT-2 INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 16 GLOBAL SULFONYLUREAS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 17 GLOBAL THIAZOLIDINEDIONE MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 18 GLOBAL DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICES 2017-2023, ($MILLION)
TABLE # 19 GLOBAL BLOOD GLUCOSE METERS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023, ($ MILLION)
TABLE # 20 GLOBAL BLOOD GLUCOSE STRIPS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 21 GLOBAL INSULIN INJECTION PENS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 22 GLOBAL INSULIN SYRINGES MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 23 GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 24 GLOBAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 25 GLOBAL LANCETS MARKET RESEARCH AND ANALYSIS 2017-2023, ($MILLION)
TABLE # 26 NORTH AMERICA DIABETES MARKET RESEARCH AND ANALYSIS BY TYPE 2017-2023, ($ MILLION)
TABLE # 27 NORTH AMERICA DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023, ($ MILLION)
TABLE # 28 NORTH AMERICA DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICE 2017-2023, ($ MILLION)
TABLE # 29 EUROPE DIABETES MARKET RESEARCH AND ANALYSIS BY TYPE 2017-2023, ($ MILLION)
TABLE # 30 EUROPE DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023, ($ MILLION)
TABLE # 31 EUROPE DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICE 2017-2023, ($ MILLION)
TABLE # 32 APAC DIABETES MARKET RESEARCH AND ANALYSIS BY TYPE 2017-2023, ($ MILLION)
TABLE # 33 APAC DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023, ($ MILLION)
TABLE # 34 APAC DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICE 2017-2023, ($ MILLION)
TABLE # 35 REST OF THE WORLD DIABETES MARKET RESEARCH AND ANALYSIS BY TYPE 2017-2023, ($ MILLION)
TABLE # 36 REST OF THE WORLD DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023, ($ MILLION)
TABLE # 37 REST OF THE WORLD DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICE 2017-2023, ($ MILLION)
FIGURE # 1 GLOBAL DIABETES MARKET SHARE BY TYPE 2016 VS 2023 (IN %)
FIGURE # 2 GLOBAL DIABETES MARKET SHARE BY DRUG CLASS 2016 VS 2023 (IN %)
FIGURE # 3 GLOBAL DIABETES MARKET SHARE BY DEVICES 2016 VS 2023 (IN %)
FIGURE # 4 GLOBAL DIABETES MARKET SHARE BY GEOGRAPHY 2016 VS 2023 (IN %)
FIGURE # 5 NORTH AMERICA DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 6 US DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 7 CANADA DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 8 EUROPEAN DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 9 UK DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 10 FRANCE DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 11 GERMANY DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 12 ITALY DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 13 SPAIN DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 14 ROE DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 15 ASIA PACIFIC DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 16 INDIA DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 17 CHINA DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 18 JAPAN DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 19 ROAPAC DIABETES MARKET SIZE 2017-2023 ($MILLION)
FIGURE # 20 REST OF THE WORLD DIABETES MARKET SIZE 2017-2023 ($MILLION)
